Ironjustic
Fri, Nov-02-07, 06:15
Haemophilia. 2007 Nov ;13 Suppl 3 :4-9 17822514 Pathogenesis
of haemophilic synovitis: clinical aspects. [My paper] W K
Hoots , N Rodriguez , L Boggio , L A Valentino Arthropathy
remains a major cause of morbidity in patients with
haemophilia. Frequent bleeding into the joints leads to joint
damage with resultant contractures, joint deformities and
arthritis. This in turn leads to muscle atrophy, limited
physical activity, osteoporosis and disability. Even though
several studies of prophylactic factor replacement for persons
with severe haemophilia demonstrate improved joint function,
this therapy is still not readily available to most people
with haemophilia around the world and a universal treatment
protocol has not been used. In this article, we discuss key
issues in the treatment of severe haemophilia: the optimal
timing of initiation and termination of therapy, dosing
options and goals of therapy. The options for countries where
prophylaxis is not readily available are also discussed. Most
studies are small and not randomized making consensus
treatment recommendations difficult to formulate. Randomized,
clinical trials are needed to provide the answers regarding
the optimal treatment of patients with severe haemophilia.
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
of haemophilic synovitis: clinical aspects. [My paper] W K
Hoots , N Rodriguez , L Boggio , L A Valentino Arthropathy
remains a major cause of morbidity in patients with
haemophilia. Frequent bleeding into the joints leads to joint
damage with resultant contractures, joint deformities and
arthritis. This in turn leads to muscle atrophy, limited
physical activity, osteoporosis and disability. Even though
several studies of prophylactic factor replacement for persons
with severe haemophilia demonstrate improved joint function,
this therapy is still not readily available to most people
with haemophilia around the world and a universal treatment
protocol has not been used. In this article, we discuss key
issues in the treatment of severe haemophilia: the optimal
timing of initiation and termination of therapy, dosing
options and goals of therapy. The options for countries where
prophylaxis is not readily available are also discussed. Most
studies are small and not randomized making consensus
treatment recommendations difficult to formulate. Randomized,
clinical trials are needed to provide the answers regarding
the optimal treatment of patients with severe haemophilia.
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk